http://www.leadingthecharge.com/stories/news-0088709.html

Eli Lilly revises Cymbalta liver warning--US FDA

Staff and agencies
21 October, 2005

Mon Oct 17, 2:32 PM ET

WASHINGTON, Oct 17 - Eli Lilly and Co. has expanded its warning about possible liver-related problems with its depression drug, Cymbalta, and cautioned doctors against use in patients with chronic liver disease, U.S. health regulators said on Monday.

A new label for the drug also includes reports of hepatitis, jaundice and other liver-related problems in patients using the drug, the Food and Drug Administration said on its Web site. The drug‘s label had earlier warned against using Cymbalta in combination with alcohol.